An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease
Biologics: Targets and Therapy · 2021-08 · Volume 15 · 363-374
DOI: 10.2147/btt.s295409 ↗At a glance
Übersichtsarbeit in Biologics: Targets and Therapy, 2021-08. Written by Mario Cazzola and 4 co-authors. Institution: Chair of Respiratory Medicine, Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy. Cited 14 times so far (Crossref); 90 references. The full text is freely available (open access, CC BY-NC 3.0).
Topics: COPD
Abstract (original language)
Several mAbs have been tested or are currently under clinical evaluation for the treatment of COPD. They can be subdivided into those that aim to block specific pro-inflammatory and pro-neutrophilic cytokines and chemokines, such as TNF-α, IL-1β, CXCL8 and IL-1β, and those that act on T2-mediated inflammation, respectively, by blocking IL-5 and/or its receptor, preventing IL-4 and IL-13 signaling, affecting IL-33 pathway and blocking TSLP. None of these approaches has proved to be effective, probably because in COPD there is no dominant cytokine or chemokine and, therefore, a single mAb cannot be effective on all pathways. With a more in-depth understanding of the numerous pheno/endotypic pathways that play a role in COPD, it may eventually be possible to identify those specific patients in whom some of these cytokines or chemokines might predominate. In this case, it will be possible to implement a personalized treatment, but the use of each mAb will only be reserved for a very limited number of subjects.
Subjects
Author keywords
Authors and institutions
- Chair of Respiratory Medicine, Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy.
- Division of Respiratory Medicine, University Hospital Tor Vergata, Rome, Italy.
- Chair of Pharmacology, Department of Experimental Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
ORCID profiles: Mario Cazzola, Josuel Ora, Paola Rogliani
Cite
APA
Cazzola, M., Ora, J., Cavalli, F., Rogliani, P., & Matera, M. G. (2021). An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease. Biologics: Targets and Therapy, Volume 15, 363-374. https://doi.org/10.2147/btt.s295409
Vancouver
Cazzola M, Ora J, Cavalli F, Rogliani P, Matera MG. An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease. Biologics: Targets and Therapy. 2021;Volume 15:363-374. doi:10.2147/btt.s295409
BibTeX
@article{Cazzola2021,
author = {Cazzola, Mario and Ora, Josuel and Cavalli, Francesco and Rogliani, Paola and Matera, Maria Gabriella},
title = {An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease},
journal = {Biologics: Targets and Therapy},
year = {2021},
volume = {Volume 15},
pages = {363--374},
doi = {10.2147/btt.s295409}
}
EUVIMED